Hypophosphatemia associated with bone marrow transplantation has been infrequently reported. The suggested mechanism is phosphate uptake by the replicating cells. Various cytokines are associated with the development of hypophosphatemia. The present study evaluated the interrelationship between cytokine release, the rise in WBC and the development of hypophosphatemia during the engraftment period. Blood samples were obtained from 60 patients undergoing peripheral blood stem cell transplant, on the day of admission and then daily from the day of transplant until discharge. Hypophosphatemia developed in 62% of the patients. The median day of minimal phosphorus level was +8 and it antedated engraftment by 2 days. There was a significant correlation between the day of minimal phosphorus level and the day of maximal WBC and a significant correlation between the fall in phosphorus level and WBC rise. IL-6 and IL-8 showed similar kinetics. Higher IL-6 and IL-8 levels were directly associated with lower phosphorus levels. In conclusion, hypophosphatemia commonly occurs in the post-transplant period. We assume that both a direct effect of cytokine release and an increased consumption by the dividing WBCs contribute to its appearance. As its occurrence usually antedates engraftment it can be used as a forerunner for WBC recovery. Bone Marrow Transplantation (2001) 27, 311-317. Keywords: hypophosphatemia; cytokines; engraftment; transplantation; WBC Several conditions are known to induce moderate to severe hypophosphatemia (HP). They include low dietary intake, conditions associated with decreased absorption or increased urinary phosphate excretion and conditions associated with shifts of phosphate from the extracellular into the intracellular fluid. The latter include various cellular 
uptake syndromes, in which HP develops as a result of phosphate consumption by rapidly proliferating cells. 1, 2 Although it is well established that rapid cell synthesis and turnover may be associated with high phosphate consumption, HP is a relatively infrequent complication of neoplastic diseases and if at all is usually associated with hyperparathyroidism due to parathyroid hormone-like peptide production. HP associated with bone marrow transplantation or peripheral blood stem cell harvesting has been seldom reported. [2] [3] [4] [5] [6] Attention has recently been focused on the in vivo release of hematopoeitic growth factors during peripheral blood stem cell transplant (PBSCT) and their relationship with stem cell engraftment. [7] [8] [9] [10] [11] [12] [13] [14] [15] A correlation was found between cytokine levels and some clinical complications post PBSCT such as acute graft-versus-host disease, noninfectious fever and the occurrence of an engraftment syndrome. 12, [15] [16] [17] [18] [19] [20] Conversely, a correlation was found between peak values of G-CSF, IL-6 and IL-8 and peak neutrophil number in the post-transplant period suggesting an important role for these cytokines in the neutrophil recovery phase. 9, 10, [13] [14] [15] [21] [22] [23] The association between HP and cytokines has recently been investigated and some authors report on HP directly induced by certain cytokines. [24] [25] [26] [27] [28] [29] [30] We have previously noticed HP antedating the rise in WBC in our patients undergoing PBSCT. Some of the patients who developed profound HP also had symptoms compatible with engraftment syndrome. We therefore decided to study prospectively the prevalence of HP in patients undergoing PBSCT and to try and establish a possible interrelationship between an increased release of certain cytokines, a rapid and steep WBC rise and the development of HP in the setting of PBSCT.
Patients and methods

Patients
Sixty patients were transplanted in the Hemato-Oncology Unit, The Chaim Sheba Medical Center (Tel-Hashomer, Israel) between April 1998 and May 1999 (Table 1) . Fiftysix patients received an autograft, while four patients had an allograft. All patients received PBSCT and none had a bone marrow stem cell transplant. The BEAM protocol (BCNU, etoposide, cytarabine and melphalan) was used as the conditioning regimen for all patients with non-Hodgkin's lymphoma or Hodgkin's disease, 31 while all patients with multiple myeloma received high-dose melphalan and etoposide except for one patient who received high-dose melphalan only. The other eight patients suffered from amyloidosis (one patient), carcinoma of the breast (two patients), acute lymphoblastic leukemia (one patient), and chronic myelogenous leukemia (four patients) and received high-dose melphalan, carboplatin, thiotepa and melphalan or busulphan and cyclophosphamide (BuCy) protocol, 32 respectively. All patients with non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma received G-CSF starting on day +4 and on day +1 for all the other patients. The day of engraftment was defined as the first day at which a neutrophil count of Ͼ0.5 × 10 9 /l was documented. Written informed consent was obtained from each patient, and the study was approved by the hospital Human Subjects Investigational Review Board.
Blood samples were usually obtained for cytokine assays, complete blood count and serum inorganic phosphate (Pi) levels on the day of admission, ie before the initiation of high-dose chemotherapy and then daily from day 0 until discharge.
Plasma cytokine assays
Blood was drawn into EDTA and plasma was separated by centrifugation (15 min at 4000 r.p.m.) shortly after collection, aliquoted and stored at −20°C until use. Early morning (7 to 8 a.m.) samples were always used for cytokine evaluation.
Plasma concentrations of the hematopoietic growth factors IL-6 and IL-8 were evaluated by sensitive and specific enzyme-linked immunosorbent assays (ELISA) (OptEIA; Parmingen, San Diego, CA, USA). These cytokines were chosen since they have previously been associated with neutrophil recovery in the post-transplant period, as well as with HP. The detection thresholds are 0.075 pg/ml and 0.1 pg/ml for IL-6 and IL-8, respectively. In addition to the controls performed by the supplier, further controls were performed to determine assay specificity (ie absence of cross-reactivity for each assay against a large panel of recombinant cytokines/proteins). Each cytokine level represents the mean value observed in two separate determinations. The intra-assay variability for the various cytokine determinations was 5% to 10%. The interassay variability of plasma cytokine immunoenzymatic analysis was 5% to 20%, using an identical immunoassay batch for each cytokine.
Serum inorganic phosphate assay
Serum Pi was assayed using a type 2 Technicon SMAC analyzer (Bayer, New York, NY, USA) using a phosphomolybdate assay. In all cases, Pi measurements were calibrated with Boehringer Manheim calibrators (Boehringer Mannheim, Lewes, UK). The between-batch coefficient of variation was 4% over the concentration range determined in this study. The laboratory reference range for serum Pi was 0.64-1.28 mmol/l. Accordingly, HP and severe HP were defined as serum Pi levels less than 0.64 mmol/l and 0.32 mmol/l, respectively.
WBC
WBC was measured using the Advia 120 Hematology system analyzer (Bayer, New York, NY, USA) using a cyanomethemoglobin flow cytometry assay. The laboratory reference range for WBC was 4.0-10.8 × 10 9 /l.
Statistical methods
Associations between the day of minimal Pi level and the day of maximal WBC level, between Pi level and WBC level and between Pi level and IL-6 and IL-8 levels were analyzed by calculating Pearson correlation coefficients, with two-tailed significance. All statistical analyses were done using SPSS software (SPSS Inc., Chicago, IL, USA).
Results
Clinical data
The median day of engraftment was +10 (range: +8-+18) and in 90% of the patients engraftment was achieved before or during day +11. Neutropenic fever Ͼ38°C was reported for 58 of the 60 patients (median, 38.9°C, range: 38.2-40.5°C) reaching its peak value on median day +5 (range 0-+11). Only 12 cases presented clinically and microbiologically documented infectious episodes. Fifty of the 60 patients had diarrhea at some stage, but none had grade 4 according to the WHO criteria. Fifty-six patients had mucositis, ranging between grades 1-4 according to the WHO criteria.
Engraftment-associated HP
The total number of blood samples assayed for Pi level and for WBC was 645 and 659 with a mean number of 10.75 and 10.98 samples per patient, respectively.
Thirty-seven of the 60 patients (62%) developed HP and 13% had severe HP. Patients were treated with phosphate supplementation as necessary and none of them developed Table 2 presents the various associations we found between Pi, WBC and cytokine levels.
Correlation between minimal Pi levels and WBC recovery
We found a statistically significant correlation between the day of minimal Pi level and the day of maximal WBC (r = 0.2793, P = 0.034) (Figure 1 ), ie the earlier the Pi reached its nadir level, the earlier the WBC reached its peak level. There was a positive correlation between the difference between baseline and minimal Pi level and the level of the WBC reached on the day following engraftment (r = 0.2887, P = 0.044) (Figure 2 ). These data suggest that as the fall in Pi level was more precipitous, the WBC level achieved was higher. Table 2 Associations between Pi, WBC and cytokine levels 
Kinetics of IL-6 and IL-8 plasma levels and correlation with Pi levels
IL-6 and IL-8 plasma levels were evaluated in 58 and in 55 of the 60 patients, respectively. The total number of blood samples obtained for IL-6 and IL-8 was 573 and 542, with a mean number of 9.87 and 9.85 samples per patient, respectively. Figure 3 depicts the kinetics of IL-6 and IL-8 on post-transplant days.
Serum IL-6 levels were low before chemotherapy and in the first days post-PBSCT. A brisk increase was noticed afterwards. The median day of maximal IL-6 level was +6 (range, 0-+12). Median maximal IL-6 level was 85.4 (range: 0-1064) pg/ml. In agreement with previous reports, IL-8 levels showed similar kinetics to those of IL-6, reaching their median peak level on day +6 (range, 0-+12) ( Figure 3 ). Median maximal IL-8 level was 153 (range, 16.8-920) pg/ml. Median and mean maximum serum cytokines in patients with HP were compared with those in patients without HP. In patients with HP, median maximum levels of IL-6 were 125.5 (range: 23.8-530) pg/ml compared with 50.9 (range: 0-61) pg/ml in patients without HP, and the mean levels were 194.1 pg/ml vs 93.5 pg/ml, respectively (P = 0.026). Median levels of IL-8 were 167.5 (range: 19.6-920) pg/ml in patients with HP vs 98.9 (range: 16.8-500) pg/ml in those without and the mean levels were 205.8 pg/ml vs 146.4 pg/ml, respectively (P = 0.194, NS). The median maximal IL-6 and IL-8 levels antedated the median minimal Pi level by 2 (range: −7-+9) and 1 (range: −7-+9) days, respectively. Both median maximal IL-6 and median IL-8 levels antedated the median engraftment day by 4 (range: −2-+11) days. Maximal IL-6 and IL-8 levels were documented before or concomitant with minimal Pi level in all but 12 of 58 and nine of the 55 evaluable patients, respectively. We found a significant correlation between maximal IL-6 and maximal IL-8 levels (r = 0.4895, P Ͻ 0.001) (Figure 4 ) and between the difference between maximal IL-6 and IL-8 levels and their levels on admission (Table 2 ). There was also a significant correlation between the day of maximal IL-6 and the day of maximal IL-8 levels ( Table 2) .
There was a significant negative correlation between maximal IL-6 level and minimal Pi level, (r = −0.3065, P = 0.019) ( Figure 5) , and between the difference between maximal IL-6 and IL-6 level on admission and minimal Pi level (Table 2) . Thus, higher IL-6 levels were associated with lower Pi levels. The same trend was also observed when maximal IL-8 and minimal Pi levels were compared and when the difference between maximal IL-8 levels and those on admission were correlated with minimal Pi level ( Table 2) . We also found a statistically significant correlation between maximal IL-6 level and the peak of the patient's temperature and between the day of maximal IL-6 and IL-8 levels and the day of peak temperature ( Table 2) .
We could not show a statistically significant correlation between the day of maximal IL-6 or IL-8 levels and the day of engraftment, or between maximal IL-6 or IL-8 levels and the rate of WBC rise or its maximal level.
Discussion
Several clinical conditions are associated with HP. The most common ones include total parenteral nutrition with high carbohydrate loading and insulin, acute respiratory and metabolic alkalosis and excessive renal loss due to druginduced tubular dysfunction. Although it is well established that rapid cell synthesis and turnover may be associated with high phosphate consumption, HP associated with bone marrow or peripheral blood stem cell transplantation has been infrequently reported. [3] [4] [5] [6] This is the first study to evaluate prospectively the prevalence of HP in patients undergoing PBSCT.
Clark and Lee 3 reported HP in association with peripheral blood stem cell harvesting. They described a CML patient who had developed severe HP concomitant with a steep rise in the WBC after receiving intensive chemotherapy and growth factor for stem cell harvesting. Crook and Schey 5 described two patients who underwent autologous bone marrow transplant and developed severe HP within 1 week after bone marrow transfusion. The same authors evaluated in a retrospective study the prevalence of HP in 17 patients who had undergone bone marrow transplant. 6 Thirteen patients had HP, two of whom had severe HP. We have previously reported the occurrence of severe HP in two autograft recipients. 4 In our patients, the precipitous fall in Pi level antedated by 2-3 days the beginning of the rapid rise in WBC and engraftment. Apart from the rapid cell rise and HP, the course of the two reported and two other unreported patients was characterized by features compatible with the engraftment syndrome mediated by cytokines. All these findings prompted us to assume that: (1) The release of certain cytokines influences the rate and maximal level of WBC rise during the post PBSCT period. (2) A rapid and steep WBC rise is associated with HP due to consumption of phosphate by the proliferating cells. (3) The release of cytokines is directly associated with the development of HP.
The high prevalence of HP, 62%, and of severe HP in 13%, in this study is similar to that described by Crook et al 6, 33 and is higher than the 2-13% prevalence reported for hospitalized patients. Of note, we defined HP as Pi level below 2 mg/dl (0.64 mmol/l), while Crook et al defined it as levels below 2.5 mg/dl (0.8 mmol/l). 6 Although we did not rule out all other causes for HP due to the relatively short hospitalization, none of our patients received total parenteral nutrition and only a few required amphotericin B, which could be potential causes for HP in this patient population. We therefore believe that the main cause for HP in this group was engraftment per se.
Our patients were monitored meticulously for Pi levels and potassium phosphate supplementation was administered as necessary. This might be the reason why none of them developed the known overt clinical complications of severe HP, including the hematological sequelae of hemolysis due to decreased ATP, a higher affinity of hemoglobin for oxygen resulting from decreased 2,3 DPG levels and impaired phagocytosis and chemotaxis of WBCs. 3, 34, 35 These events might be even more deleterious for this group of post-transplant patients.
The median day of minimal Pi level antedated that of Bone Marrow Transplantation engraftment by a median of 2 days. This lag period is compatible with the transit time between WBC production in the bone marrow and their appearance in the peripheral blood. 2 The direct relationship between the rate of Pi fall and that of WBC rise, manifested by the positive correlations between the fall in Pi levels and the WBC level reached 1 day post engraftment or the rate of WBC rise (Table 2) , confirms our assumption that the rapidly dividing WBC progenitors consume phosphate for their production, thus contributing to the development of HP.
IL-6 and IL-8 are pro-inflammatory cytokines involved in inflammatory reactions and in many adverse conditions associated with PBSCT. 9, 12, 14, 15, 20, 36, 37 IL-6 is an important component in the regulation of normal hematopoietic activity and its levels after transplantation have been widely determined, but IL-8 levels less so. We showed similar kinetics for IL-6 and IL-8, both reaching their peak levels on day +6 and preceding the hematologic recovery, as evaluated by the WBC (Figure 3 ). This was in agreement with previous reports which also showed maximal peak levels of the same cytokines around day +6 and a coordinate release of both, with a strong correlation between their plasma levels in the post-transplant period, as well as in non-hematological situations. 7, 9, 10, 13, 15, 36 The synchronous wave of IL-8 and IL-6 secretion suggests that a similar mechanism underlies the production of these cytokines. Since IL-6 has no stimulatory effect on IL-8, the same agents are probably stimulating IL-6 and IL-8 production in parallel. This mechanism may be in part represented by the early production of IL-3 and GM-CSF. 9, 13 Our findings showing that peak values of IL-6 and IL-8 antedated peak WBC number in the recovery period and the basic information about the biologic activity of these cytokines strongly suggests their role in WBC recovery. Although there was a trend, we could not show a statistically significant correlation between the day of maximal IL-6 or IL-8 levels and the day of engraftment although such a correlation has been reported. 13, [21] [22] [23] The fact that maximal IL-6 and IL-8 levels antedated minimal Pi levels which in turn preceded engraftment, and the significant correlation between the day of minimal Pi level and that of maximal WBC suggests that there is a sequence of events in the post-transplant period in which the rise of certain cytokines heralds the fall in Pi level, which in itself predicts WBC rise. HP can therefore be used as an early sign for engraftment.
The role of cytokines in the pathogenesis of HP has recently been reported in association with IL-2 administration and sepsis. Webb et al 28 and Belldegrun et al 30 reported on HP developing in renal cell cancer patients treated with IL-2. Other authors reported on severe HP induced by hepatic arterial infusion of recombinant TNF␣ in patients with liver metastases. 26, 27 Barak et al 24 who investigated the role of cytokines in the development of sepsis associated HP, found elevated levels of IL-6 and TNF␣ in patients with sepsis. The raised levels of these cytokines correlated with HP recorded during the first 24 h of sepsis. When injected into mice, the inflammatory cytokines IL-1␤, IL-6, IL-8 and TNF␣ had a direct effect, inducing HP. Recently another cytokine, recombinant IL-12, was found to affect Pi levels upon injection in squirrel monkeys. 25 The correlation in our study between higher IL-6 and IL-8 levels and lower Pi levels (Table 2 ) supports the assumption that HP is at least partly directly caused by the release of cytokines also in the post-transplant period.
The significant correlation between maximal IL-6 or IL-8 levels and maximal temperature level is in accordance with previous reports, which showed that IL-6 and IL-8 profiles correlated well with febrile episodes. 9, 11 In conclusion, HP commonly prevails in the context of PBSCT. We assume that it is caused by two complementary mechanisms, both initiated by the release of certain cytokines: the first through a direct effect on Pi levels and the second through consumption of phosphate by the rapidly dividing WBC whose rise is in turn induced by these cytokines. Further studies are necessary to confirm these data and to evaluate the interrelationship between Pi levels and other hematopoietic factors released in the post-transplant period.
